PPi Editor Andy Myall
andymyall@stepcomms.com
Science Editor Brian Nation CSci FIBMS
briannation@stepcomms.com
Publisher Geoff King
geoffking@stepcomms.com
Business Manager Peter Moon
petermoon@stepcomms.com
Journal Administration Katy Cockle
katycockle@stepcomms.com
Design Laurence Hallam
Publishing Director Trevor Moon
trevormoon@stepcomms.com
Advisory Panel Dr Nigel Brown FIBMS Gavin Knight CSci FIBMS Wendy Leversuch CSci FIBMS Dr Suzy Lishman CBE FRCPath Dr Stephen MacDonald FRCPath Prof Gerry McKenna DSc CSci FIBMS Malcolm Needs CSci FIBMS Dr Sarah Pitt CSci FIBMS Dr John Rees FIBMS
Pathology in Practice may not be reproduced in any way without prior written consent of the publisher.
Step House, North Farm Road Tunbridge Wells Kent TN2 3DR Tel: 01892 779999
Email:
info@pathologyinpractice.com ISSN 1465-9131
Register your details to receive free copies of the magazine. SCAN HERE
Creating a Community of Practice, see page 21
Securing the future of digital pathology NEWS ARTICLES
Management of risk: an action plan for pulling everything together
Building a resilient future: establishing a Community of Practice
Detection to direction: the future of precision oncology diagnostics
Hyperviscosity syndrome: a complication hiding in plain sight?
Precision oncology diagnostics, see page 27
Tackling sepsis and antimicrobial stewardship
GENie: specialist Genomic Online Individual Education from GenQA
POC PlGF testing: a paradigm shift in pre-eclampsia diagnosis
POCT Innovators event: The power to disrupt through diagnostics
Point-of-care PlGF testing, see page 50
Phaeochromocytoma and paraganglioma: testing for rare neuroendocrine tumours
Detection to direction: precision oncology diagnostics Oncology diagnostics are evolving from detecting cancer to guiding decisions
15 21 27 31 38 44 50 54 56 COVER STORY
across the entire patient journey. Screening is shifting from population-based tests to biomarker-led approaches such as Proclarix in prostate cancer, improving accuracy and reducing unnecessary investigations. Diagnostic precision is further enhanced by molecular tools like the Prostatype Genomic Classifier, which more accurately predicts prostate cancer outcomes than traditional methods and supports decisions such as active surveillance or focal therapy. Treatment selection is also being shaped by predictive biomarkers; for example, MAF gene testing in breast cancer helps identify patients more likely to benefit from adjuvant bisphosphonate therapy. As diagnostics advance, integration of laboratory systems, data, and clinical delivery has become essential. Source BioScience supports this shift by combining accredited cellular pathology with molecular and genomic testing capabilities, enabling end-to-end diagnostic pathways.
T: 0115 973 9012 E:
enquiries@sourcebioscience.com W:
www.sourcebioscience.com
WWW.PATHOLOGYINPRACTICE.COM DECEMBER 2025 3 5 7
CONTENTS
Volume 26 Issue 8 December 2025
www.pathologyinpractice.com OPINION
PATHOLOGY IN PRACTICE
PPi PIP cover
Dec25.indd 1
www.pathologyinpractice.com VOLUME 26 • ISSUE 8 • DECEMBER 2025
MANAGEMENT OF RISK: PULLING TOGETHER AN ACTION PLAN
COMPLICATION HIDING IN PLAIN SIGHT? A RESILIENT FUTURE: ESTABLISHING
A COMMUNITY OF PRACTICE HYPERVISCOSITY SYNDROME:
DETECTION TO DIRECTION The future of precision oncology diagnostics
14/11/2025 10:56
PATHOLOGY IN PRACTICE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
